The Center for New Drug Safety Evaluation and Research, Inner Mongolia Medical University, Hohhot, China.
The Center for New Drug Screening Engineering and Research of Inner Mongolia Autonomous Region, Inner Mongolia Medical University, Hohhot, China.
Drug Dev Ind Pharm. 2021 Jul;47(7):1175-1182. doi: 10.1080/03639045.2021.1988100. Epub 2021 Oct 12.
The use of metal-organic framework (MOF) platforms has been a topic of growing interest in the fields of drug delivery and bioimaging. This study was designed to develop and evaluate a novel MOF-based drug and radiation delivery nanosystem.
Eu-MOFs were characterized via X-ray diffraction, scanning electronic microscopy, and FT-IR spectrometry. Nanocarrier uptake and associated cell viability were assessed using a CCK-8 assay and using a high content screening system. Biodistribution studies were conducted with a Luminal II IVIS imaging system to assess nanocarrier distribution in different organs. As such, paclitaxel was selected as a model drug in the present study to evaluate Eu-MOF drug loading and release characteristics via HPLC.
A straightforward one-step approach was used to successfully fabricate sea urchin-shaped Eu-MOFs that were self-assembled from Eu and 1,3,5-pyromellitic acid. These MOFs exhibited robust red fluorescence owing to the antenna effect. Owing to their fluorescent properties, these Eu-MOFs were able to facilitate imaging with a high quantum yield and low background signal. Importantly, our Eu-MOFs exhibited good biocompatibility, low cytotoxicity, and high imaging efficiency. As they exhibited slow-release kinetics and targeted biodistribution profiles, these Eu-MOFs additionally hold great promise as potential anti-cancer agents in clinical settings.
Herein, we designed a novel Eu-MOF active targeted drug delivery nanocarrier platform and found that it represents a promising therapeutic tool for cancer treatment.
金属-有机骨架(MOF)平台的应用在药物输送和生物成像领域已成为研究热点。本研究旨在开发和评估一种新型基于 MOF 的药物和辐射递药纳米系统。
通过 X 射线衍射、扫描电子显微镜和傅里叶变换红外光谱对 Eu-MOFs 进行了表征。使用 CCK-8 测定法和高内涵筛选系统评估了纳米载体摄取及其相关细胞活力。使用 Luminal II IVIS 成像系统进行了生物分布研究,以评估纳米载体在不同器官中的分布情况。因此,本研究选择紫杉醇作为模型药物,通过 HPLC 评估 Eu-MOF 的药物负载和释放特性。
采用简单的一步法成功制备了由 Eu 和 1,3,5-均苯三甲酸自组装而成的海胆状 Eu-MOF。这些 MOF 由于天线效应表现出强的红色荧光。由于其荧光特性,这些 Eu-MOF 能够实现高量子产率和低背景信号的成像。重要的是,我们的 Eu-MOF 具有良好的生物相容性、低细胞毒性和高成像效率。由于其表现出缓慢释放动力学和靶向生物分布特征,这些 Eu-MOF 作为临床潜在的抗癌药物具有广阔的应用前景。
本研究设计了一种新型 Eu-MOF 主动靶向药物输送纳米载体平台,发现其为癌症治疗提供了一种有前途的治疗工具。